Compare TMO & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMO | NVS |
|---|---|---|
| Founded | 1956 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.4B | 254.8B |
| IPO Year | N/A | 1991 |
| Metric | TMO | NVS |
|---|---|---|
| Price | $570.86 | $132.26 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 20 | 4 |
| Target Price | ★ $630.42 | $118.00 |
| AVG Volume (30 Days) | 1.6M | ★ 1.8M |
| Earning Date | 01-29-2026 | 01-30-2026 |
| Dividend Yield | 0.30% | ★ 1.96% |
| EPS Growth | ★ 8.54 | N/A |
| EPS | ★ 17.32 | 7.30 |
| Revenue | $43,736,000,000.00 | ★ $56,372,000,000.00 |
| Revenue This Year | $4.33 | $9.33 |
| Revenue Next Year | $4.94 | $2.75 |
| P/E Ratio | $33.05 | ★ $18.16 |
| Revenue Growth | 3.22 | ★ 12.88 |
| 52 Week Low | $385.46 | $96.06 |
| 52 Week High | $610.97 | $134.24 |
| Indicator | TMO | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 57.20 |
| Support Level | $561.91 | $130.46 |
| Resistance Level | $579.08 | $133.84 |
| Average True Range (ATR) | 10.97 | 1.68 |
| MACD | -2.81 | 0.13 |
| Stochastic Oscillator | 26.08 | 75.78 |
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.